Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Reviewed By Analysts

Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Its quick ratio for most recent quarter is 6.30 along with current ratio for most recent quarter of 6.30.

The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share repurchases and debt reduction. Canada Pension Plan Investment Board increased its position in Agios Pharmaceuticals by 31.8% in the third quarter. (AGIO). These ratios are important while doing valuation of the company or the shares of the company. (NASDAQ:AGIO). Free cash flow represents the amount of cash that a company has generated for shareholders after paying off expenses and investing in growth. (AGIO) reported its EPS in the last quarter as $-1.34/Share beating the analyst estimate of $-1.51/Share by the difference of $0.17. TIAA CREF Investment Management LLC now owns 84,412 shares of the biopharmaceutical company's stock worth $4,459,000 after buying an additional 3,636 shares in the last quarter. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

08/08/2016 - Agios Pharmaceuticals, Inc. had its " rating reiterated by analysts at Goldman Sachs. On Tuesday, February 21 NELSEN ROBERT sold $6.68 million worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) or 135,364 shares.

Agios Pharmaceuticals (NASDAQ:AGIO) has insider ownership of 10.55% and institutional ownership of 88.79%. The firm's market cap is $2.13 billion. Agios Pharmaceuticals has recorded a 50-day average of $53.56 and a two hundred day average of $50.53.

According to sentiments of 9 analysts the mean estimates of short term price target for the company's stock is marked at $62.89. This showed the surprise of 13.6% in the last quarter earnings. They expect $-1.83 EPS, down 200.00% or $1.22 from last year's $-0.61 per share. The company's year to date (YTD) performance is at 20.68%. The stock has earnings growth of -24.30% yoy and showed a high EPS growth of 10.60% over the past five years. Analysts forecast that Agios Pharmaceuticals Inc will post ($7.31) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and global copyright laws.

08/19/2016 - BTIG Research began new coverage on Agios Pharmaceuticals, Inc. giving the company a "neutral" rating. The stock has "Buy" rating by SunTrust on Wednesday, March 30. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has a Return on Assets (ROA) of -35.40%.

Investors may be interested in viewing the Gross Margin score on shares of Agios Pharmaceuticals, Inc. They now have a Dollars 75 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of "Buy" and a consensus target price of $63.54. The shares were sold at an average price of $55.00, for a total value of $354,090.00. Insiders now own 0.50% of total outstanding shares. About 758,153 shares traded or 77.09% up from the average. The number of shares now owned by investors are 42.23 mln. The disclosure for this sale can be found here.

The company declined -3.22% and closed its last trading session at $50.36.

Agios Pharmaceuticals, a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Recommended News

  • Pakistan's top court rules prime minister can stay in power

    Pakistan's top court rules prime minister can stay in power

    Pakistan's stock market jumped after the decision, with the Karachi Stock Exchange's benchmark KSE100 gaining nearly 2 percent. Reports said the joint investigation team will consist of members of Pakistan's Inter-Services Intelligence (ISI).
    Oracle to buy digital-ad analytics firm Moat

    Oracle to buy digital-ad analytics firm Moat

    Oracle said it will continue to invest in Moat and to include more functionality and capabilities, brought to market at a quicker pace.

    North Korean propaganda video threatens U.S. with missiles

    Next week, US Secretary of State Rex Tillerson will chair a minister-level meeting on the North Korean issue at the UN. We've said it as clearly as we can possibly say it.
  • Bill O'Reilly show axed amid sexual harassment scandal

    But how many more changes can Fox News withstand? It's also home to ambitions that the O'Reilly crisis may have hindered. Just hours after shaking hands with Pope Francis , he was sacked from Fox News amid sexual harassment allegations.
    Sean Payton testifies at Cardell Hayes' sentencing

    Sean Payton testifies at Cardell Hayes' sentencing

    Saints Head Coach Sean Payton testified about Smith's character and described him as an extremely smart, passionate man. Hayes' defense said after the trial that Smith's popularity led to a rush to judgment by police and prosecutors.

    'The sword stands ready': US VP Mike Pence warns North Korea

    China is regarded as a major influence on North Korea and the U.S. has sought its support in influencing the rogue state. China, he said with a bluntness that is rare here, had fundamentally botched its policy on the divided Korean Peninsula.
  • US President Orders Changes to H1-B Visa Program

    Trump complained that today's H-1B visa system is a mess, with visas being awarded at random in a lottery . To qualify for the visa, workers usually must have a bachelor's degree or higher.
    Arkansas court allows state to use execution drug

    Arkansas court allows state to use execution drug

    The Arkansas Supreme Court said in a 4-3 ruling that it would not reconsider its decision to stay Johnson's execution. Johnson and Ledell Lee, the other prisoner who was scheduled to be executed tonight, both say they are innocent.

    Senators reject proposal to cut taxes in road-funding bill

    HB21 increases the basic allotment given per student in lieu of a transportation allotment. It works to equalize how much state money school districts across Texas receive.
  • Mike Pence warns North Korea: 'The sword stands ready'

    That kind of rhetoric has unnerved allies in Japan and South Korea, who would be at the sharp end of any North Korean response. The North has said such launches are an act of deterrence against a potential invasion by the United States or South Korea.

    A new high: Poll finds record support for pot legalization

    The nation's most populous state simply decided it would stop prosecuting sick people for using pot. Generally speaking, though, global marijuana prohibitions are thawing just as they are in the U.S.

    Sweet drinks linked to dementia

    Having at least one diet drink a day increased the risk compared to consuming less than one diet drink a week, a study found. They were also examined using MRIs (magnetic resonance imaging) and cognitive testing to measure their thinking and memory.

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.